Earnings per share for the last twelve months: TScan Therapeutics Inc (TCRX)
TScan Therapeutics (TCRX) maintains its position thanks to T-Scan platform innovations in solid tumor therapy. The annual earnings per share trend on the GURU.Markets chart demonstrates that -0.91 represents the current metric level. The business relies on a closed scientific circuit with licenses for pharma behemoths, overcoming the challenges of costly production and strict regulatory oversight in the oncology sector.
Metric breakdowns and analytics for TScan Therapeutics Inc (TCRX)
- share price and expert price forecast:
- company stock exchange capitalization indicators:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
Debt to Equity TScan Therapeutics|TCRX - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital TScan|TCRX - Company Total Debt|Debts to Book Capitalization TScan Therapeutics, Inc.|TCRX - Company Long-Term Debts|Company Short-Term Debt TScan Therapeutics|Quick Liquidity Indicator tscan.com
- net income and valuation multiples indicators:
TCRX - Final Profit|Future Profit TScan Therapeutics|TCRX - Market Price to Net Income Ratio|Forward P/E Multiple TScan|TCRX - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple TScan Therapeutics, Inc.|TCRX - Profit before interest, taxes and amortization|Earnings per share for the last twelve months TScan Therapeutics|TCRX - Earnings per share for the trailing year|Quarterly EPS earnings growth tscan.com|TCRX - Earnings growth in current year|Net earnings per share growth forecast for next year TScan Therapeutics
Initial company analysis:tscan.com (TCRX)
Earnings per share (EPS TTM) determines the portion of total income allocated to a single security over a year. This metric is calculated by dividing net profit by the number of shares outstanding. By analyzing the trend of net income per share, an investor identifies the efficiency of capital management. For TScan Therapeutics (TCRX), this indicator reflects the cost of investments in T-cell therapy. High expenditures on expert teams and target discovery directly impact the final value of this metric.
Competitors of TScan Therapeutics (TCRX)
ONC: Net earnings per share for the last 12 months|HALO - Net earnings per share (EPS TTM)|Revolution Medicines, Inc. (RVMD) - Earnings per share for the last twelve months|Ascentage Pharma Group International - Earnings per share for the trailing year|CGON (CG Oncology Corp) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months UroGen Pharma Corp URGN|Net earnings per share for the last 12 months BCAX (Bicara Therapeutics Inc.)|Earnings per share for the last four quarters PSNL|Earnings per share for the last twelve months Erasca ERAS|Net earnings per share for the last four quarters Delcath Systems Inc (DCTH)|YmAbs - Net earnings per share (EPS TTM)|Aura Corp (AURA) - Net earnings per share for the last 12 months|CADL: Net earnings per share (EPS TTM)|accuray.com (ARAY) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months SELLAS Life Sciences Group, Inc.|Earnings per share for the last 12 months ACTU (Actuate Therapeutics Inc.)|Net earnings per share for the last 12 months CTOR (Citius Oncology, Inc)|HURA (tuhurabio.com) - Earnings per share for the trailing year|Protara Therapeutics - Net earnings per share for the last 12 months|Earnings per share for the last four quarters FATE (fatetherapeutics.com)|Aadi Bio - Net earnings per share (EPS TTM)|Earnings per share for the trailing year CSBR (Champions Oncology)|XBIT: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months CEL-SCI (CVM)|Earnings per share for the last twelve months OS Therapies Incorporated|RADX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) ARTV|Net earnings per share (EPS TTM) adlainortye.com (ANL)|Earnings per share for the last twelve months Veru Pharma VERU|TPST (Tempest Therapeutics Corp) - Earnings per one share for the last 12 months|Xilio - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Renovaro Inc.|MURA (muraloncology.com) - Net earnings per share for the last 12 months|Kairos Pharma (KAPA) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months OKUR|GDTC (CytoMed) - Earnings per share for the last four quarters|Net earnings per share (EPS TTM) CRIS|Net earnings per share for the last four quarters apollomicsinc.com|Net earnings per share (EPS TTM) THAR (Tharimmune)|ADVB - Net earnings per share for the last 12 months|GNPX - Earnings per share for the last twelve months|Net earnings per share for the last four quarters Calidi Biotherapeutics CLDI|SBFM (Sunshine Biopharma, Inc.) - Net earnings per share for the last 12 months|XBIO: Earnings per share for the last four quarters|SLRX (Salarius Pharmaceuticals, Inc.) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Purple Biotech Ltd (PPBT)|Earnings per share for the last twelve months American Oncology Network (AONC)|BGNE (BeiGene Ltd) - Earnings per share for the trailing year|Checkpoint Therapeutics - Net earnings per share for the last 12 months|ELEV: Earnings per share for the last 12 months|iCAD Corp - Net earnings per share (EPS TTM)|Ikena Oncology, Inc. (IKNA) - Net earnings per share for the last 12 months|NTBL: Net earnings per share (EPS TTM)|Viracta Therapeutics, Inc. (VIRX) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months MorphoSys AG|Earnings per share for the last 12 months NAYA (nayabiosciences.com)|Net earnings per share (EPS TTM) AAPGV
